FIELD: biotechnology.
SUBSTANCE: pharmaceutical composition containing an effective amount of a bispecific antibody containing an antigen-binding fragment against human CD3E and an antigen-binding fragment against human BCMA, and a pharmaceutically acceptable carrier, excipient or diluent are presented.
EFFECT: invention makes it possible to use it for the prevention or treatment of multiple myeloma.
6 cl, 10 dwg, 6 tbl, 12 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| TETANUS TOXIN ANTIBODY AND USE THEREOF | 2020 |
|
RU2815280C1 |
| HUMAN TSLP ANTIBODIES AND USE THEREOF | 2021 |
|
RU2825460C1 |
| ANTI-TSLP ANTIBODY AND USE THEREOF | 2020 |
|
RU2834227C1 |
| ANTI-BCMA ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF | 2020 |
|
RU2819660C2 |
| ANTI-CLDN-18.2 ANTIBODY AND USE THEREOF | 2021 |
|
RU2829997C1 |
| ANTIBODY TO B7-H4, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2792748C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| ANTI-FXI/FXIA ANTIBODY, ANTIGEN-BINDING FRAGMENT AND PHARMACEUTICAL APPLICATION THEREOF | 2021 |
|
RU2838408C1 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
